2022-502866-25-00已完成1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer AG
- 入组人数
- 86
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (1)
Loading locations...
相似试验
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
招募中
2 期
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors2023-507141-28-00Sanofi-Aventis Recherche & Developpement115
招募中
1 期
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)NCT07282847AskBio Inc12
招募中
1 期
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis2023-503679-12-00Janssen - Cilag International75
已完成
不适用
A first in human sequential dose-escalation study investigating safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of NS11821 in healthy male subjectsanxiety disorder10002861anxietyNL-OMON33125eurosearch40